Kornimate/medical-research-clean huggingface dataset:
assessment of probiotics lactobacillus in the management of attention deficit hyperactive disorder

Conditions: Inattentive; Hyperactivity; Impulsivity

Summary: adhd is a neurodevelopmental disorder characterized by persistent symptoms of inattention and/or hyperactivity and impulsivity that are present before age 18. these symptoms must be evident across adhd treatment is currently based on a multimodal approach with the combination of psychotherapy and pharmacotherapy, but no reliable markers of treatment response have been identified yet and 20-35% of subjects in clinical trials may have an inadequate response to the treatment the gut microbiome refers to the microbial ecosystem found in the gastrointestinal system of the human species probiotics are a type of beneficial bacteria that improve health and facilitate intestinal microbial balance increasing evidence suggests that the gut microbiota plays a key role in the gut-brain communication axis by influencing metabolism, inflammation, the hypothalamic-pituitary-adrenal axis, and neurotransmission multiple domains and cause impairment in functioning in order to meet the diagnostic criteria for adhd

all patients will be randomly distributed into two equal groups using a random number generator from computer-based randomization software. the probiotic group (n=40) received probiotic preparation twice daily (lacteol forte; rameda, egypt) as sachets containing 10 billion colony-forming units (cfu) of lactobacillus fermentum and lactobacillus delbruekii for 12 weeks added to a weight-dependent dose of standard treatment (atomoxetine), and the 40 patients in the control group will not receive the probiotic and on a weight-dependent dose of atomoxetine.

Eligibility criteria:
inclusion criteria: * age from 6 to 16 years old. * children fulfilled dsm(v) criteria for adhd syndrome. exclusion criteria: * intelligence quotient (iq) less than 80% . * presence of other medical conditions as chronic medical or neuropsychiatric disorders e.g diabetes mellitus, epilepsy.....etc. hearing or visual impairment, or medications side effects. * currently taking probiotics or antibiotics

Keywords: hyperactivity inattention probiotics
the epidemiology of ventricular assist device-related infections

Conditions: Congestive Heart Failure

Summary: infections often occur after ventricular assist devices (vads) are placed. these infections can be very serious. the goal of this study is to understand why these infections occur. bacteria (germs) normally live on our skin and in our noses. after surgery, they can infect the vad. the investigators will collect cultures of your skin and nose before and after surgery. the investigators will compare these bacteria to bacteria that cause infections. their genes will be compared to see which ones help the bacteria cause infection.

infections are one of the most serious of ventricular assist device (vad) related complications. many of these infections are associated with significant patient morbidity and mortality. diagnosis of these infections is often difficult due to the complicated nature of the patient's medical problems, the need for rapid institution of empiric antibiotic therapy and the lack of established criteria that define infection. staphylococci are among the most common causes of vad infections. the basis for this high incidence is not well understood but is believed to be in part due to inoculation of staphylococcal commensal flora into wound sites at the time of surgery or thereafter. the goals of this observational study are to develop a better understanding of the pathogenesis and epidemiology of staphylococcus aureus and epidermidis-vad infections as well as to develop a set of criteria that can be used to help diagnose the presence or absence of a vad related infection. this is a prospective, multi-center, observational study to identify risk factors associated with the development of vad-related infections. patients will be followed for up to one year following vad implantation, time of death or transplantation, whichever comes first. there will be no randomization for this observational study.

Eligibility criteria:
inclusion criteria: 1. age greater than or equal to 18 years. 2. approved by the institution's heart failure/transplant committee for vad implantation, either as a bridge to cardiac transplantation or for destination therapy for end-stage heart failure. 3. signed informed consent, release of medical information, and hipaa forms. 4. expectation of compliance with protocol procedures and study visit schedule.
peri-articular-multimodal drug and oral celecoxib in management of postoperative pain of total knee arthroplasty

Conditions: Postoperative Pain; Total Knee Arthroplasty

Summary: this study is a randomized-clinical-trial on 146 patients candidate for total knee arthroplasty (tka) who were randomly allocated to three treatment groups, including 1) a cocktail consisting of bupivacaine, morphine, epinephrine, and ketorolac (n=48), 2) only epinephrine (placebo group) (n=49), and 3) 400mg celecoxib orally (control group) (n=49) using random allocation software. the injections and oral therapy were performed within 15 minutes before the surgical procedure. the study's primary outcome was the knee society score (kss) calculated at baseline, within six weeks and six months postoperatively. range of motion (rom) and visual analogue scale (vas) to assess pain intensity as the other primary outcomes were evaluated before the procedure, within 24 hours, 48 hours, and six weeks postoperatively.

this randomized clinical trial conducted on 146 patients undergone tka in orthopedic hospitals affiliated at isfahan university of medical science (iums) in 2021. the presence of osteoarthritis, making the patients candidate for primary unilateral total knee arthroplasty (tka), and body mass index of 20-30 kg/m2 were determined as inclusion criteria. the regional bioethics committee of iums approved the study protocol. this study was designed as a census study; therefore, all the patients who met the criteria for participation in this study were recruited. participants were randomly divided into three groups using random allocation software, so each patient was provided with a specific number from 1-to-146 by the software and allocated to one of the groups. the investigator who performed the baseline and follow-up assessments and the patients were unaware of the study group; as the investigator was absent at the time of the surgery and all the patients administered a pill prior to the surgical procedure (one group was treated with celecoxib and the other two ones administered placebo similar in shape and color with celecoxib). the primary outcome was the knee society score (kss) calculated at baseline, within six weeks and six months postoperatively. range of motion (rom) and visual analogue scale (vas) to assess pain intensity as the other primary outcomes were evaluated before the procedure, within 24 hours, 48 hours, and six weeks postoperatively.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of osteoarthritis * candidate for primary unilateral tka * body mass index of 20-30 kg/m2 exclusion criteria: * unable to follow-up the assessments * having more than 20% defects in medical records

Keywords: total knee arthroplasty pain multimodal analgesia range of motion
acute effects of tcig vs ecig in plwh

Conditions: E Cigarette Use; Vaping; Smoking; Tobacco Smoking; Nicotine Use Disorder; Qt Interval, Variation in; HIV I Infection; Oxidative Stress; Inflammation

Summary: randomized controlled trial of acute use of electronic cigarette or tobacco cigarette on parameters of ventricular repolarization and inflammation/oxidative stress.

on separate days, participants will undergo 3 different exposures: an acute e-cigarette exposure, an acute tobacco cigarette exposure, and a sham (empty e-cigarette) control . before and after the acute exposure, participants will have blood drawn for inflammation/oxidative stress markers and undergo a 5-minute ecg recording.

Eligibility criteria:
inclusion criteria: chronic (\> 1year) tcig smoker hiv positive stable art viral count non-detectable cd4 \>500 exclusion criteria: known major illness (heart disease, diabetes, lung or liver disease) daily recreational drug use, including cannabis \>2 alcoholic drinks per day obesity (\>30 kg/m2) recent (\<3 months) infection
examining the relationships between sleep, fatigue, and pain in aromatase inhibitor-treated patients

Conditions: Breast Cancer

Summary: aromatase inhibitors are commonly prescribed for treatment of postmenopausal women with breast cancer. these medications can cause side effects in some women, and occasionally they can be quite bothersome. we are doing a study to better understand the side effects of aromatase inhibitors so that we can hopefully treat them better or possibly prevent them. in particular, we are interested in pain and difficulty sleeping. this study is designed to assess the effect of aromatase inhibitors on pain, sleep quality, and fatigue and the interplay of these side effects and their subsequent impact on daily activity. each participant will fill out a series of questionnaires about pain, sleep quality, and fatigue and will also complete a sleep diary and wear an actigraphy watch for 10 days before starting an aromatase inhibitor and after taking it for 3 months. we hope to learn more about these symptoms so we can better manage medication toxicity in the future.


Eligibility criteria:
inclusion criteria: * female, aged 50 years or older, postmenopausal. * patients with histologically proven stage 0-iii invasive carcinoma of the breast that is estrogen receptor and/or progesterone receptor positive by immunohistochemical staining, who are planning to start treatment with a standard dose of aromatase inhibitor (ai) therapy. * subjects must have undergone surgical resection of their primary tumor, as indicated. the most recent surgery must have been performed at least 4 weeks before the baseline evaluation and no additional surgeries (including reconstructive procedures) should be planned during study participation. * cytoxic chemotherapy, if applicable, must have been completed at least 4 weeks before the baseline evaluation. * radiation therapy, if applicable, must have been completed at least 2 weeks before baseline evaluation. * eastern cooperative oncology group performance status 0-2. * ability to operate the accelerometer exclusion criteria: * diagnosis of sleep apnea or restless leg syndrome. * use of a wheelchair for ambulation most of the time. * second or third shift workers or other non-traditional sleep schedules. * history of medical arthritic disease that could confound or interfere with evaluation of pain or activity level, including but not limited to inflammatory arthritis (rheumatoid arthritis, systemic lupus, spondyloarthropathy, psoriatic arthritis, polymyalgia rheumatica), parkinson's disease, and cancer involving the bone. * serious or unstable medical condition that could likely lead to hospitalization during the course of the study or compromise study participation

Keywords: breast cancer aromatase inhibitors actigraphy pain fatigue sleep quality
study of otamixaban versus unfractionated heparin (ufh) and eptifibatide in non-st elevation acute coronary syndrome

Conditions: Coronary Disease

Summary: primary objective: to demonstrate the clinical efficacy of otamixaban (dose effect via 5 intravenous \[iv\] regimens) in patients with moderate-to-high-risk non-st elevation acute coronary syndromes (acs) and planned early invasive strategy. secondary objectives: to evaluate safety and assess pharmacokinetics (pk) and pharmacodynamics (pd).


Eligibility criteria:
inclusion criteria: * ischemic discomfort at rest ≥ 10 minutes within 24 hours of randomization * electrocardiogram (ecg) criteria for non-st elevation acs or cardiac enzyme elevation (\> upper limit of normal \[uln\]) * no st elevation myocardial infarction (stemi) * planned coronary angiography followed when indicated by a percutaneous coronary intervention (pci) on day 1 to day 3 exclusion criteria: * inability to undergo coronary angiography or pci by day 3 * prior pci within 30 days * acute stemi * cardiogenic shock * anticoagulant treatment for \> 24 hours prior to randomization * prior treatment with fondaparinux since acs onset * requirement for oral anticoagulant (oac) prior to day 30 * creatinine clearance \< 30 ml/min

Keywords: non st elevation acute coronary syndrome early invasive strategy percutaneous coronary intervention
non-interventional study of celsentri® in treatment experienced patients with ccr5-tropic hiv-infection

Conditions: HIV-1

Summary: aim of the study is to gain more knowledge about efficacy of celsentri® in daily clinical practice and obtain information about the quality of life of patients using celsentri®.

non interventional study, inclusion and exclusion criteria defined by the labelling of celsentri (maraviroc).

Eligibility criteria:
inclusion criteria: hiv-1 infection. ccr-5 tropic virus. therapy experienced patient, exclusion criteria: x4 or d/m tropic virus. therapy-naive patients.

Keywords: hiv-1 non-interventional ccr-5 tropic virus therapy experienced patients
uva 1 phototherapy for vitiligo

Conditions: Vitiligo

Summary: vitiligo is a chronic acquired disease characterized by well defined white macules and patches affecting the skin. there are many treatment modalities available for vitiligo, however, none of them cure the disease. ultraviolet a1 (uva1) phototherapy has been shown to be useful for a variety of skin diseases. however, there are only a few studies published on the efficacy of uva1 in vitiligo. this is a prospective single-blind randomized clinical trial to assess efficacy and safety of uva1 in the treatment of vitiligo.

vitiligo is a chronic acquired disease characterized by well defined white macules and patches affecting the skin and mucous membranes. mucocutaneous lesions develop secondary to selective destruction of melanocytes. the etiology of vitiligo is largely unknown but more likely to be multifactorial. there are several theories on the pathogenesis of vitiligo including mainly the autoimmune, neurohormonal, and autocytotoxic theories. the autoimmune hypothesis has the strongest evidence with alteration mainly in the cellular immune response. there are many treatment modalities available for vitiligo, however, none of them cure the disease. these include different topical treatments, phototherapy, surgical therapy, and depigmentation therapy. narrow-band uvb (nb-uvb) is currently the preferred treatment over topical psoralen and ultraviolet a radiation (puva), for patients with vitiligo. however, overall response of vitiligo to nb-uvb has been variable. ultraviolet a1(uva1) phototherapy is now useful for a variety of skin diseases, specifically scleroderma. there are only a few studies published on the efficacy of uva1 in vitiligo. one of the main side effects of uva1 is prominent tanning which might be due to melanocyte stimulation. therefore, the investigators hypothesis is that uva1 will induce significant skin pigmentation to improve vitiligo. the investigators plan on conducting a prospective single-blind randomized clinical trial to assess efficacy and safety of uva1 in the treatment of vitiligo. study objectives 1. to evaluate the potential for uva1 to induce repigmentation within vitiligo patches. 2. to assess the side effect profile of uva1 when used in the treatment of vitiligo.

Eligibility criteria:
inclusion criteria: * age \> 18 years. * localized or generalized vitiligo that involves a non mucosal or acral site. * patients should have a patch of at least 25 cm2 that shows no more than 10% repigmentation as assessed visually exclusion criteria: * patients who received treatment for vitiligo within the past 3 weeks. * patients known to have a photosensitivity disorder * history of previous skin cancer. * history of severe medical illness or immunosuppression. * pregnancy or breast-feeding.

Keywords: vitiligo uva1 phototherapy
effect of probiotics on mycoplasma pneumoniae pneumonia

Conditions: Mycoplasma Pneumoniae Pneumonia

Summary: to evaluate the effectiveness and safety of compound probiotic in shortening the course of illness in children with mycoplasma pneumoniae pneumonia, in comparison with placebo.


Eligibility criteria:
inclusion criteria: 1. meet the diagnostic criteria for pneumonia in "zhufutang practical pediatrics" (7th edition), and is diagnosed with mycoplasma pneumoniae pneumonia using tngs technology; 2. infants and young children aged 6 months to 3 years; 3. the course of the disease is \<48 h; 4. the family members of the children are informed about the study and sign the informed consent form. exclusion criteria: 1. previous history of wheezing; 2. cardiovascular disease and congenital tracheal dysplasia; 3. pneumonia induced by other causes; 4. dysplasia of bronchial and pulmonary tracts; 5. premature infants; 6. combined with immunosuppressive diseases; 7. presence of mental illness.
treating depressed mood with a smartphone-delivered positive word stimulation for subthreshold depression

Conditions: Subthreshold Depression

Summary: major depressive disorder (mdd) is an important public health problem. thus, preventive interventions against subthreshold depression (std), which is one of the key risk factors for the development of mdd, are important. the study developed a smartphone application (spsrs) that improves depressive symptoms in people with std by automatically presenting positive word stimuli during videos. the spsrs application has the potential to improve depressive symptoms in people with stds. however, whether it can immediately improve depressed moods in people with std is unclear. the study aims to investigate the immediate effects of spsrs applications on depressed mood in people with std.


Eligibility criteria:
inclusion criteria: 1. male and female 2. 20 to 39 years old 3. beck depression inventory-ii (bdi-ii) score of 10 points or more 4. persons with written informed consent prior to participation exclusion criteria: 1. history of mental illness 2. currently receiving treatment from a professional for mental health issues 3. vision or hearing problems that interfere with daily life. 4. with a major depressive episode in the last two weeks according to the mini-international neuropsychiatric interview
a study of the incidence of intraocular inflammation and suspected endophthalmitis among patients treated with aflibercept, vial and pre-filled syringe, 2014-2022

Conditions: Intraocular Inflammation; Suspected Endophthalmitis

Summary: specific study objectives include: * to describe patient and provider characteristics for aflibercept patients and aflibercept user injections by aflibercept dispensing device, overall, and stratified by time (quarterly, annually). * to estimate the annual and quarterly incidence of intraocular inflammation (ioi) and suspected endophthalmitis for aflibercept user injections by aflibercept dispensing device. secondary objectives • to estimate the annual incidence of ioi and suspected endophthalmitis for aflibercept user injections by dispensing device, stratified by indication for use, history of ioi, and provider characteristics.

this study is entirely descriptive using secondary data from the vestrum health retina treatment and outcomes database.

Eligibility criteria:
inclusion criteria for a treatment episode: 1. must have received one or more injections of aflibercept, regardless of indication, between 01jan2014 to 30apr2022 2. patients must have at least one eligible treatment episode a. specification of laterality of aflibercept injection (left or right eye or both) for treatment episode exclusion criteria for a treatment episode: 1. a post-operative follow-up visit for any ocular surgery (excluding vitrectomy), within +/-28 days of aflibercept injection, as defined in the protocol 2. active steroid treatment, defined as steroid treatment (topical or intravitreal) on the date of aflibercept injection. this criterion is limited to date of aflibercept injection since steroids may be used to treat iois. 3. any treatment episode where a patient eye receives \>1 (or an unknown) anti-vegf injection on the index date (date of aflibercept injection).

Keywords: age-related macular degeneration anti-vascular endothelial growth factor diabetic macular edema diabetic retinopathy endophthalmitis intraocular inflammation retinal vein occlusion vascular endothelial growth factor
trigger finger corticosteroid injection with and without local anesthetic

Conditions: Trigger Finger

Summary: steroid injection is the first line treatment for trigger finger. steroid injection is sometimes mixed with a local anesthetic.

the treatment of trigger finger involves an injection of corticosteroid. corticosteroid treats the underlying inflammatory pathology. some surgeons add lidocaine with epinephrine as a local anesthetic with the injection. lidocaine with epinephrine is associated with a burning sensation and may be the primary pain associated with the injection. we hypothesize that a corticosteroid injection without lidocaine with epinephrine will be less painful, and equally effective in treating trigger finger

Eligibility criteria:
inclusion criteria: * at least 18 years old with trigger finger exclusion criteria: * preference for open trigger finger release * not a candidate for corticosteroid injection * contraindication to lidocaine with epinephrine
a study to assess the effect of single and multiple doses org 50081 and a single dose of zopiclone on next-day driving ability and psychomotor performance in healthy volunteers. (p05794) (completed)

Conditions: Sleep Initiation and Maintenance Disorders; Mental Disorders

Summary: this trial is to investigate the effect on next-day driving performance and psychomotor performance in healthy volunteers.


Eligibility criteria:
inclusion criteria: * subject has at least 3 years of car driving experience * subject signs the trial informed consent form * subject is in a healthy condition as judged by the investigator * subject has a regular sleep pattern exclusion criteria: * subject has insomnia or any other sleep disorder * medication or drug use of any kind prior to the study * relevant history or presence of a significant medical illness
exploring cultural acceptability of community breast cancer risk assessment among hispanic women in maricopa county

Conditions: Breast Carcinoma; Breast Cancer; Breast Cancer Female

Summary: this study explores the cultural acceptability of community breast cancer risk assessment among hispanic women in maricopa county.

primary objectives: i. examine the association between perceived risk and mammography screening behavior and differences in perceived risk by patient characteristics in hispanic women screened at mountain park health center (mphc). ii. characterize attitudes, beliefs, and barriers towards mammography screening and cultural acceptability of brca models in community settings using focus group and interview data from under- and uninsured hispanic women in maricopa county. outline: this is an observational study. participants attend an interview or participate in a focus group on study.

Eligibility criteria:
inclusion criteria: * aim 1: * completed a baseline survey for the latinas learning about density (llead) study * self-identify as hispanic * between 40-65 years of age * aim 2: * between the ages of 45 and 65 * self-identify as hispanic * current residence in maricopa county * be under- (e.g. arizona health care cost containment system) or uninsured at the time of enrollment * can read and speak english or spanish well enough to understand and complete the informed consent process and take part in either a focus group or individual interview exclusion criteria: * aim i: * women with a history of breast cancer * aim 2: * women with a history of breast cancer